Journal article · 2021 · Open access
Medical Device Industry Approaches for Addressing Sources of Failing Cytotoxicity Scores
Biomedical Instrumentation & Technology, 55(2), 69–84 · Published 1 May 2021 · DOI 10.2345/0899-8205-55.2.69
In brief
“Medical Device Industry Approaches for Addressing Sources of Failing Cytotoxicity Scores” is a 2021 journal article by Helin Räägel and 6 co-authors, published in Biomedical Instrumentation & Technology. OpenAlex counts 17 citations as of 15 November 2026, which puts it in the top 5% of works published in 2021 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 17
- Most cited in
- 2023 (5)
- Field-weighted impact
- 1.64
- References
- 81
- Authors
- 7
Abstract
To ensure patient safety, medical device manufacturers are required by the Food and Drug Administration and other regulatory bodies to perform biocompatibility evaluations on their devices per standards, such as the AAMI-approved ISO 10993-1:2018 (ANSI/AAMI/ISO 10993-1:2018).However, some of these biological tests (e.g., systemic toxicity studies) have long lead times and are costly, which may hinder the release of new medical devices. In recent years, an alternative method using a risk-based approach for evaluating the toxicity (or biocompatibility) profile of chemicals and materials used in medical devices has become more mainstream. This approach is used as a complement to or substitute for traditional testing methods (e.g., systemic toxicity endpoints). Regardless of the approach, the one test still used routinely in initial screening is the cytotoxicity test, which is based on an in vitro cell culture system to evaluate potential biocompatibility effects of the final finished form of a medical device. However, it is known that this sensitive test is not always compatible with specific materials and can lead to failing cytotoxicity scores and an incorrect assumption of potential biological or toxicological adverse effects. This article discusses the common culprits of in vitro cytotoxicity failures, as well as describes the regulatory-approved methodology for cytotoxicity testing and the approach of using toxicological risk assessment to address clinical relevance of cytotoxicity failures for medical devices. Further, discrepancies among test results from in vitro tests, use of published half-maximal inhibitory concentration data, and the derivation of their relationship to tolerable exposure limits, reference doses, or no observed adverse effect levels are highlighted to demonstrate that although cytotoxicity tests in general are regarded as a useful sensitive screening assays, specific medical device materials are not compatible with these cellular/in vitro systems. For these cases, the results should be analyzed using more clinically relevant approaches (e.g., through chemical analysis or written risk assessment).
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Räägel, H., Turley, A. P., Fish, T. J., Franson, J., Rollins, T. S., Campbell, S., & Jorgensen, M. R. (2021). Medical Device Industry Approaches for Addressing Sources of Failing Cytotoxicity Scores. Biomedical Instrumentation & Technology, 55(2), 69–84. https://doi.org/10.2345/0899-8205-55.2.69
MLA 9
Räägel, Helin, et al. “Medical Device Industry Approaches for Addressing Sources of Failing Cytotoxicity Scores.” Biomedical Instrumentation & Technology, vol. 55, no. 2, 2021, pp. 69–84. https://doi.org/10.2345/0899-8205-55.2.69.
Chicago
Räägel, Helin, Audrey P. Turley, Trevor J. Fish, Jeralyn Franson, Thor S. Rollins, Sarah Campbell, and Matthew R. Jorgensen. 2021. “Medical Device Industry Approaches for Addressing Sources of Failing Cytotoxicity Scores.” Biomedical Instrumentation & Technology 55 (2): 69–84. https://doi.org/10.2345/0899-8205-55.2.69.
Harvard
Räägel, H. et al. (2021) ‘Medical Device Industry Approaches for Addressing Sources of Failing Cytotoxicity Scores’, Biomedical Instrumentation & Technology, 55(2), pp. 69–84. doi:10.2345/0899-8205-55.2.69.
IEEE
H. Räägel et al., “Medical Device Industry Approaches for Addressing Sources of Failing Cytotoxicity Scores,” Biomedical Instrumentation & Technology, vol. 55, no. 2, pp. 69–84, 2021, doi: 10.2345/0899-8205-55.2.69.
BibTeX
@article{raagel2021medical,
title = {{Medical Device Industry Approaches for Addressing Sources of Failing Cytotoxicity Scores}},
author = {Räägel, Helin and Turley, Audrey P. and Fish, Trevor J. and Franson, Jeralyn and Rollins, Thor S. and Campbell, Sarah and Jorgensen, Matthew R.},
journal = {Biomedical Instrumentation \& Technology},
year = {2021},
volume = {55},
number = {2},
pages = {69--84},
doi = {10.2345/0899-8205-55.2.69},
url = {https://doi.org/10.2345/0899-8205-55.2.69}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 5 | |
| 2024 | 3 | |
| 2025 | 5 | |
| 2026 | 4 |
Its field-weighted citation impact is 1.64: it has been cited 1.64 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
- cytotoxicity assay
- medical device biocompatibility
- toxicological risk assessment
- systemic toxicity
- half maximal inhibitory concentration
- no-observed-adverse-effect level
- reference dose
- regulatory compliance
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Räägel, H., Turley, A. P., Fish, T. J., Franson, J., Rollins, T. S., Campbell, S., & Jorgensen, M. R. (2021). Medical Device Industry Approaches for Addressing Sources of Failing Cytotoxicity Scores. Biomedical Instrumentation & Technology, 55(2), 69–84. https://doi.org/10.2345/0899-8205-55.2.69
How many times has this paper been cited?
17 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at PubMed Central.
Who wrote this paper?
Helin Räägel, Audrey P. Turley, Trevor J. Fish, Jeralyn Franson, Thor S. Rollins, Sarah Campbell, Matthew R. Jorgensen.
What is the DOI of this paper?
10.2345/0899-8205-55.2.69. The permanent link is https://doi.org/10.2345/0899-8205-55.2.69.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.